Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $13.65, for a total value of $22,317.75. Following the completion of the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $117,622.05. The trade was a 15.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Scott Bizily also recently made the following trade(s):

• On Tuesday, September 1st, Scott Bizily sold 584 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $8,176.00.
• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $19,620.00.
• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total value of $19,947.00.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT traded up $0.64 during midday trading on Tuesday, reaching $15.88. 936,611 shares of the company traded hands, compared to its average volume of 831,720. The firm has a market cap of $877.21 million, a PE ratio of -6.04 and a beta of 2.74. The stock’s 50-day simple moving average is $12.87 and its 200-day simple moving average is $10.90. 4D Molecular Therapeutics, Inc. has a 12 month low of $6.96 and a 12 month high of $16.93. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. As a group, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. Cantor Fitzgerald upgraded 4D Molecular Therapeutics from a “neutral” rating to an “overweight” rating and set a $20.00 price target on the stock in a research report on Monday, September 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, B. Riley Financial reissued a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $28.56.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of large investors have recently modified their holdings of the stock. Jupiter Topco LLC acquired a new position in 4D Molecular Therapeutics during the 2nd quarter worth $76,466,000. BlackRock Inc. acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $60,463,000. Janus Henderson Group PLC raised its position in shares of 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after acquiring an additional 611,276 shares during the last quarter. Trails Edge Capital Partners LP acquired a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $29,631,296. Finally, Bank of America Corp DE acquired a new position in shares of 4D Molecular Therapeutics during the second quarter valued at $14,905,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc is a clinical-stage biotechnology company developing genetic medicines for serious diseases with significant unmet medical needs. The company uses its Therapeutic Vector Evolution platform to engineer and select adeno-associated virus (AAV) vectors designed to deliver genetic payloads to specific tissues and support the development of potentially durable, one-time treatments.

Its research and development programs have focused primarily on ophthalmic and pulmonary diseases.